CHRONIC LYMPHOCYTIC LEUKEMIA

This study is testing whether a new COVID-19 booster vaccine (called GEO-CM04S1) works better than the current standard mRNA boosters for people with chronic lymphocytic leukemia (CLL), a type of cancer that weakens the immune system. The trial will enroll 80 adults with CLL who …

This study is testing whether a combination of two drugs, acalabrutinib and obinutuzumab, can control chronic lymphocytic leukemia (CLL) for a period of time without needing continuous treatment. The main goal is to see if patients can stop all therapy and remain in remission for…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study aims to compare the effectiveness and safety of a new oral drug called pirtobrutinib against the standard drug ibrutinib for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It will enroll about 660 participants, some who have had pri…

This study is testing a new version of a cancer treatment called CAR T-cell therapy for adults with certain B-cell lymphomas or leukemias that have come back or not responded to other treatments. The researchers are modifying a patient's own immune cells in the lab to potentially…

This study is testing whether a drug called mosunetuzumab, given alone or with other leukemia medications, can clear very low levels of lingering cancer cells in people with chronic lymphocytic leukemia (CLL). The goal is to see if this approach can help control the disease bette…

This study is testing whether a drug called Glofitamab works better alone or when combined with other cancer drugs to treat Richter's Transformation. This is a fast-growing lymphoma that can develop in people with chronic lymphocytic leukemia. About 70 adults with this condition …

This study is for veterans with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a standard daily pill (like ibrutinib). It will test if adding a second pill, venetoclax, for one year leads to better cancer control and, importantly, al…

This study is testing whether a daily pill called APG-2575 can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to standard treatments. About 75 adults whose cancer has progressed after previous therapies…

This early-stage trial is testing the safety and initial effectiveness of a new three-drug combination for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The treatment combines two antibody drugs (tafasitamab and obinutuzu…

This study is for people who have already been taking the drug pirtobrutinib for chronic lymphocytic leukemia or non-Hodgkin lymphoma in a previous trial. Its main purpose is to monitor the long-term safety of the drug and track how long patients live. It allows participants from…

This study is testing whether a combination of three drugs—pirtobrutinib, venetoclax, and obinutuzumab—can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after prior treatment. It will enroll about 40 adults who have been tr…

This study is for adults with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not yet needed treatment but are at high risk of their disease getting worse. It compares a cancer-fighting pill (acalabrutinib) taken alone to the same pill …

This study aims to find the safest way to start a combination drug treatment for adults with a common type of blood cancer called chronic lymphocytic leukemia (CLL). Researchers are testing different dosing schedules for the drug venetoclax when given with two other medicines to …

This early-stage trial is testing the safety and early effectiveness of a new type of CAR T-cell therapy called azer-cel in adults whose B-cell blood cancers have returned or not responded to prior treatments. The therapy uses donor immune cells (allogeneic) engineered to target …

This study is testing whether adding a drug called epcoritamab to standard treatment can help patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve a deeper remission. The goal is to see if this combination can eliminate nearly all cancer ce…

This study is testing whether adding a new drug called emavusertib to an existing cancer medication (zanubrutinib) can better control chronic lymphocytic leukemia and similar blood cancers. It will enroll 108 adults who are already taking zanubrutinib but need additional treatmen…

This large, late-stage study aims to see if a new oral drug called nemtabrutinib works as well as or better than current standard drugs (ibrutinib or acalabrutinib) for people newly diagnosed with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocyt…

This study aims to understand how the drug zanubrutinib works for adults with certain blood cancers in everyday clinic settings, not a controlled trial. It will follow about 705 patients to see how the treatment affects their quality of life, how often they need hospital care, an…

This study is testing whether adding a new immune-boosting drug (epcoritamab) to a standard two-drug treatment can lead to better and longer-lasting results for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see …

This study is testing a personalized approach for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior treatment. It uses a combination of two approved drugs first, then checks with a very sensitive b…

This study aims to collect long-term safety and effectiveness data for patients with various blood cancers who are already taking the drug ibrutinib and benefiting from it. It provides continued access to the medication for about 700 participants who were in previous ibrutinib st…

This study is testing a modified, two-step stem cell transplant procedure designed to be safer. It aims to reduce deaths caused by the transplant treatment itself in patients with various blood cancers and disorders. The trial compares two gentler preparation methods using lower …

This study is testing if adding a drug called venetoclax to a patient's current ibrutinib or acalabrutinib treatment can help eliminate more cancer cells. It is for adults with high-risk chronic lymphocytic leukemia (CLL) who have been on one of those drugs for at least a year bu…

This study is testing a new oral medication called BGB-16673 for people with various B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors. It is for adults …

This early-stage study is testing the safety and initial effectiveness of a new drug, mosunetuzumab, both by itself and in combination with another drug called venetoclax. It is for adults with chronic lymphocytic leukemia (CLL) that has come back or is not responding to current …

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This study is testing three different doses of an experimental drug called pirtobrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma whose cancer has returned or worsened after previous treatment with a specific type of medication called a BTK inhib…

This study is testing whether starting a two-drug cancer treatment early, before patients have any symptoms, leads to better survival for people with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It will compare starting treatment immediately v…

This study is testing whether adding a targeted drug called polatuzumab vedotin to standard chemotherapy works better for people with Richter's transformation, a serious complication where chronic lymphocytic leukemia turns into a more aggressive lymphoma. About 20 adults with th…

This study tracks the long-term safety and survival of people with chronic lymphocytic leukemia or non-Hodgkin lymphoma who have already taken pirtobrutinib in earlier clinical trials. It allows participants from completed Lilly-sponsored studies to continue receiving the drug or…

This is a first-in-human study to find a safe dose of an experimental drug called CC312 for adults with certain B-cell blood cancers that have come back or stopped responding to other therapies. The main goal is to check the drug's safety and how the body processes it in about 44…

This study is testing whether a new drug called BGB-16673 works better than standard treatments for people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to previous medications. About 150 participants in China and Taiwan w…

This study aims to understand and better manage high blood pressure and heart risks in people with certain blood cancers who are taking a specific type of medication called a BTK inhibitor. Researchers will closely monitor 100 patients for one year to see how often these side eff…

This is the first study in people testing an experimental oral drug called ABBV-525 for several types of advanced B-cell blood cancers, including lymphoma and leukemia. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it …

This early-phase study is testing a new type of treatment called CAR-T cell therapy for adults with advanced B-cell blood cancers that have returned or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them in a lab to better reco…

This is a first-in-human study to test the safety of a new oral drug called SGR-1505 in adults with various types of relapsed or hard-to-treat B-cell cancers, like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to find the highest dose patients can tolera…

This study is testing if a faster, higher dose increase of a new drug called sonrotoclax is safe and tolerable for patients with certain blood cancers. It is for adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), inclu…

This study is testing a combination of three drugs—acalabrutinib, venetoclax, and durvalumab—to see if they can help control a rare and aggressive cancer called Richter transformation. Richter transformation occurs when a slower-growing blood cancer (CLL) suddenly changes into a …

This study is testing a new oral medication called AS-1763 for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The trial will enroll a…

This is the first study in people to test a new drug called ABBV-319 for several types of blood cancer that have come back or stopped responding to other treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it mig…

This study is testing whether a new drug called sonrotoclax works better than the current standard treatment, venetoclax, for adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to previous therapies. About 630 participants w…

This study is testing whether taking one of two drugs less often works as well as taking it continuously for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 62 participants will be randomly assigned to receive the dru…

This study is testing whether combining two oral medications, pirtobrutinib and venetoclax, can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients whose cancer has continued to grow despite treatment with standard BTK inhibitor drugs. The m…

This study is testing a new drug called BGB-16673 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has come back or stopped responding after two common types of targeted therapies. About 250 participants worldwide will be randoml…

This study aims to see if a new investigational drug, BGB-16673, works better and is as safe as an existing drug, pirtobrutinib, for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior treatment. It will involv…

This study is testing whether adding a second drug to acalabrutinib helps achieve deeper remission in people with previously untreated chronic lymphocytic leukemia (CLL). After one year on acalabrutinib alone, participants will be randomly assigned to receive either obinutuzumab …

This study is testing a one-year treatment plan for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants will take the drug pirtobrutinib for six months, then add obinutuzumab for another six months, after which all trea…

This study is testing a new three-drug combination for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal is to see how many participants achieve a state where no cancer cells can be detected by a very sensitive …

This study is testing a new combination of two drugs, nemtabrutinib and pembrolizumab, for patients with Richter transformation, a fast-growing type of lymphoma. The goal is to see if using these drugs together is safe and can shrink or control the cancer. The trial will enroll a…

This study is testing whether adding a new oral drug, roginolisib, to two standard drugs (venetoclax and rituximab) is safe and works better for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. About 64 participants will receiv…

This study aims to see if a new combination of drugs (sonrotoclax plus zanubrutinib) works better and is safer than a current standard combination (venetoclax plus acalabrutinib) for people newly diagnosed with chronic lymphocytic leukemia (CLL). It will involve about 500 adults …

This study aims to collect blood and tissue samples to help develop a single blood test that can detect many different cancers early. Researchers will enroll 2,000 people, including those with cancer and those without, to create a reference set for testing. The goal is to validat…

This early-stage trial is testing a new vaccine designed to prevent serious cytomegalovirus (CMV) infections. The study involves patients with blood cancers who are receiving a stem cell transplant from a partially matched donor, a procedure that carries a high risk of CMV. Resea…

This study is testing if giving two different pneumonia vaccines in a series works better to protect people with chronic lymphocytic leukemia (CLL). CLL weakens the immune system, making patients very vulnerable to serious lung infections. Researchers want to see if this two-vacc…

This study is testing a new vaccine approach to prevent a common and serious viral infection called CMV in patients receiving a stem cell transplant for blood cancers. Researchers are giving the vaccine to the healthy stem cell donors, hoping the donor's boosted immunity will be …

This study is testing whether giving pneumococcal vaccines more frequently provides better protection for people with chronic lymphocytic leukemia (CLL). The trial will compare the standard 5-year vaccination schedule against more frequent yearly vaccinations in 80 CLL patients w…

This study is testing whether a common vitamin called nicotinamide (a form of vitamin B3) can prevent new non-melanoma skin cancers in people who have chronic lymphocytic leukemia (CLL) and a history of these skin cancers. About 86 participants will take either the vitamin or a p…

This study aims to understand how different oral treatment schedules for chronic lymphocytic leukemia (CLL) affect patients' quality of life and daily functioning. Researchers will follow 132 adults in Spain who are already receiving standard oral treatments, either for newly dia…

This study aims to understand how a drug called acalabrutinib affects the daily life and well-being of people with chronic lymphocytic leukemia (CLL). Researchers will look back at health records and quality-of-life surveys from about 120 patients in France over the first year of…

This study aims to understand how two related blood conditions—monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)—affect the bone marrow's ability to produce cells that fight infections. Researchers will compare blood and bone marrow samples from 50 peop…

This study aims to understand how chronic lymphocytic leukemia (CLL) cells use nutrients like sugar and glutamine to grow and survive. Researchers will track these nutrients in blood and bone marrow samples from 16 adults with CLL and some healthy volunteers. The goal is to find …

This study aims to learn how the drug venetoclax affects cancer cells and the immune system in people with chronic lymphocytic leukemia (CLL). Researchers will observe 75 adults with relapsed CLL as they start treatment, tracking genetic changes in the cancer over time. The goal …

This study aims to understand how well the drug acalabrutinib works for treating chronic lymphocytic leukemia (CLL) in everyday medical practice in Belarus. Researchers will observe about 50 adult patients who have just started taking this medication and follow them for two years…

This study aims to understand why some patients with chronic lymphocytic leukemia (CLL) stop responding to two common types of targeted drugs. Researchers will collect blood, bone marrow, and lymph node samples from 60 patients whose cancer has become resistant to both drug types…

This study aims to monitor the long-term health of 500 patients who have already received CAR-T cell therapy for various blood cancers in earlier trials. Researchers will follow these patients for up to 15 years to check for any late-developing side effects, such as new cancers o…

This study collects health information from patients receiving stem cell transplants for various blood cancers and immune disorders. Researchers will track 2,000 patients over time to gather data on survival rates and treatment complications. The goal is to build a comprehensive …

This study aims to understand how well lymphoma patients' immune systems respond to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 patients with various lymphoma types, comparing them over time. The goal is to learn how cancer treatments …

This study tracks healthcare costs and patient quality of life for Canadians with high-risk chronic lymphocytic leukemia. It compares starting newer treatments immediately versus waiting until symptoms appear. Researchers will follow 247 patients for up to 10 years to understand …

This study aims to understand how often irregular heartbeats occur in cancer patients starting BTK inhibitor medications. Researchers will implant small heart monitors in 50 patients to continuously track their heart rhythms for up to five years. The goal is to see how frequently…

This study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…